Arsenic trioxide prevents nitric oxide production in lipopolysaccharide -stimulated RAW 264.7 by inhibiting a TRIF-dependent pathway

Cancer Science

Volumn 104, Issue 2, 2013, Pages 165-170

  Takahashi, Miyuki ^a,b   Ota, Akinobu ^a   Karnan, Sivasundaram ^a   Hossain, Ekhtear ^a   Konishi, Yuko ^a   Damdindorj, Lkhagvasuren ^a   Konishi, Hiroyuki ^a   Yokochi, Takashi ^c   Nitta, Masakazu ^b   Hosokawa, Yoshitaka ^a  

^a Department of Internal Medicine ^*  (Japan)

^b Department of Internal Medicine   (Japan)

^c AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; BETA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERFERON REGULATORY FACTOR 3; LIPOPOLYSACCHARIDE; MESSENGER RNA; NITRIC OXIDE; STAT1 PROTEIN; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1;

ANIMAL CELL; ARTICLE; FLOW CYTOMETRY; GENE EXPRESSION; IMMUNE RESPONSE; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ADAPTOR PROTEINS, VESICULAR TRANSPORT; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIGENS, CD14; ANTINEOPLASTIC AGENTS; ARSENICALS; INTERFERON REGULATORY FACTOR-3; INTERFERON-BETA; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MYELOID DIFFERENTIATION FACTOR 88; NF-KAPPA B; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; OXIDES; PHOSPHORYLATION; RNA, MESSENGER; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; TOLL-LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84873738385     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12053     Document Type: Article

References (34)

1. Zhu J, Chen Z, Lallemand-Breitenbach V, de The H. How acute promyelocytic leukaemia revived arsenic. Nat Rev Cancer 2002; 2: 705-13.
2. Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008; 111: 2505-15.
3. Zhang XW, Yan XJ, Zhou ZR et al. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science 2010; 328: 240-3.
4. Lallemand-Breitenbach V, Jeanne M, Benhenda S et al. Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat Cell Biol 2008; 10: 547-55.
5. Tatham MH, Geoffroy MC, Shen L et al. RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat Cell Biol 2008; 10: 538-46.
6. Li J, Chen P, Sinogeeva N et al. Arsenic trioxide promotes histone H3 phosphoacetylation at the chromatin of CASPASE-10 in acute promyelocytic leukemia cells. J Biol Chem 2002; 277: 49.
7. Chou WC, Chen HY, Yu SL, Cheng L, Yang PC, Dang CV. Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood 2005; 106: 304-10.
8. Mathieu J, Besançon F. Arsenic trioxide represses NF-kappaB activation and increases apoptosis in ATRA-treated APL cells. Ann N Y Acad Sci 2006; 1090: 203-8.
9. Bobe′ P, Bonardelle D, Benihoud K, Opolon P, Chelbi-Alix MK. Arsenic trioxide: syndromes in MRL/lpr mice. Blood 2006; 108: 3967-75.
10. Bogdan C. Nitric oxide and the immune response. Nat Immunol 2001; 2: 907-16.
11. Nathan C. Nitric oxide as a secretory product of mammalian cells. FASEB J 1992; 6: 3051-64.
12. Nathan C, Shiloh MU. Reactive oxygen and nitrogen intermediates in the relationship between mammalian hosts and microbial pathogens. Proc Natl Acad Sci USA 2000; 97: 8841-8.
13. Bogdan C, Röllinghoff M, Diefenbach A. Reactive oxygen and reactive nitrogen intermediates in innate and specific immunity. Curr Opin Immunol 2000; 12: 64-76.
14. Xie K, Dong Z, Fidler IJ. Activation of nitric oxide gene for inhibition of cancer metastasis. J Leukoc Biol 1996; 59: 797-803.
15. Pervin S, Singh R, Chaudhuri G. Nitric oxide-induced cytostasis and cell cycle arrest of a human breast cancer cell line (MDA-MB-231): potential role of cyclin D1. Proc Natl Acad Sci USA 2001; 98: 3583-8.
16. Shibata K, Yoshimura Y, Kikuiri T et al. Effect of the release from mechanical stress on osteoclastogenesis in RAW264.7 cells. Int J Mol Med 2011; 28: 73-9.
17. Zheng H, Yu X, Collin-Osdoby P, Osdoby P. RANKL stimulates inducible nitric-oxide synthase expression and nitric oxide production in developing osteoclasts. An autocrine negative feedback mechanism triggered by RANKL-induced interferon-beta via NF-kappaB that restrains osteoclastogenesis and bone resorption. J Biol Chem 2006; 81: 15. 809-20.
18. Impellizzeri D, Di Paola R, Esposito E et al. CGS 21680, an agonist of the adenosine (A2A) receptor, decreases acute lung inflammation. Eur J Pharmacol 2011; 668: 305-16.
19. Hamid Q, Springall DR, Riveros-Moreno V et al. Induction of nitric oxide synthase in asthma. Lancet 1993; 342: 1510-13.
20. Sordillo JE, Webb T, Kwan D, Kamel J, Hoffman E, Milton DK. Allergen exposure modifies the relation of sensitization to fraction of exhaled nitric oxide levels in children at risk for allergy and asthma. J Allergy Clin Immunol 2011; 127: 1165-72.
21. Chakravortty D, Kato Y, Sugiyama T et al. The inhibitory action of sodium arsenite on lipopolysaccharide-induced nitric oxide production in RAW 267.4 macrophage cells: a role of Raf-1 in lipopolysaccharide signaling. J Immunol 2001; 166: 2011-17.
22. Hosokawa Y, Suzuki H, Nakagawa M, Lee TH, Seto M. API2-MALT1 fusion protein induces transcriptional activation of the API2 gene through NF-kappaB binding elements: evidence for a positive feed-back loop pathway resulting in unremitting NF-kappaB activation. Biochem Biophys Res Commun 2005; 334: 51-60.
23. Ota A, Yamamoto M, Hori T et al. Upregulation of plasma CCL8 in mouse model of graft-vs-host disease. Exp Hematol 2009; 37: 525-31.
24. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124: 783-801.
25. Kleinert H, Pautz A, Linker K, Schwarz PM. Regulation of the expression of inducible nitric oxide synthase. Eur J Pharmacol 2004; 500: 255-66.
26. Toshchakov V, Jones BW, Perera PY et al. TLR4, but not TLR2, mediates IFN-beta-induced STAT1alpha/beta-dependent gene expression in macrophages. Nat Immunol 2002; 3: 392-8.
27. Lowenstein CJ, Snyder SH. Nitric oxide, a novel biologic messenger. Cell 1992; 70: 705.
28. Goldring CE, Reveneau S, Algarté M, Jeannin JF. In vivo footprinting of the mouse inducible nitric oxide synthase gene: inducible protein occupation of numerous sites including Oct and NF-IL6. Nucleic Acids Res 1996; 24: 1682-7.
29. Yamamoto M, Sato S, Hemmi H et al. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 2003; 301: 640-3.
30. Gao JJ, Filla MB, Fultz MJ, Vogel SN, Russell SW, Murphy WJ. Autocrine/paracrine IFNα/β mediates the lipopolysaccharide-induced activation of transcription factor Stat1α in mouse macrophages: pivotal role of Stat1α in induction of the inducible nitric oxide synthase gene. J Immunol 1998; 161: 4803-10.
31. Meraz MA, White JM, Sheehan KC et al. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 1996; 84: 431-42.
32. Ohmori Y, Hamilton TA. Requirement for STAT1 in LPS-induced gene expression in macrophages. J Leukoc Biol 2001; 69: 598-604.
33. Chen GQ, Zhu J, Shi XG et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 1996; 88: 1052-61.
34. Shao W, Fanelli M, Ferrara FF et al. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells. J Natl Cancer Inst 1998; 90: 124-33.